ToxStrategies, Inc., Hudson, MA, USA.
Havlik-Wall Professor of Oncology, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Crit Rev Toxicol. 2020 Sep;50(8):685-706. doi: 10.1080/10408444.2020.1823934. Epub 2020 Nov 4.
Small intestinal (SI) tumors are relatively uncommon outcomes in rodent cancer bioassays, and limited information regarding chemical-induced SI tumorigenesis has been reported in the published literature. Herein, we propose a cytotoxicity-mediated adverse outcome pathway (AOP) for SI tumors by leveraging extensive target species- and site-specific molecular, cellular, and histological mode of action (MOA) research for three reference chemicals, the fungicides captan and folpet and the transition metal hexavalent chromium (Cr(VI)). The gut barrier functions through highly efficient homeostatic regulation of SI epithelial cell sloughing, regenerative proliferation, and repair, which involves the replacement of up to 10 cells per day. This dynamic turnover in the SI provides a unique local environment for a cytotoxicity mediated AOP/MOA. Upon entering the duodenum, cytotoxicity to the villous epithelium is the molecular initiating event, as indicated by crypt elongation, villous atrophy/blunting, and other morphologic changes. Over time, the regenerative capacity of the gut epithelium to compensate declines as epithelial loss accelerates, especially at higher exposures. The first key event (KE), sustained regenerative crypt proliferation/hyperplasia, requires sufficient durations, likely exceeding 6 or 12 months, due to extensive repair capacity, to create more opportunities for the second KE, spontaneous mutation/transformation, ultimately leading to proximal SI tumors. Per OECD guidance, biological plausibility, essentiality, and empirical support were assessed using modified Bradford Hill considerations. The weight-of-evidence also included a lack of induced mutations in the duodenum after up to 90 days of Cr(VI) or captan exposure. The extensive evidence for this AOP, along with the knowledge that human exposures are orders of magnitude below those associated with KEs in this AOP, supports its use for regulatory applications, including hazard identification and risk assessment.
小肠(SI)肿瘤在啮齿动物癌症生物测定中相对少见,已发表的文献中有限的信息涉及化学诱导的 SI 肿瘤发生。在此,我们利用三种参考化学物质(杀真菌剂克菌丹和灭菌丹以及过渡金属六价铬(Cr(VI))的广泛目标物种和特定部位的分子、细胞和组织学作用机制(MOA)研究,提出了一个与 SI 肿瘤相关的细胞毒性介导的不良结局途径(AOP)。肠道屏障通过高效的 SI 上皮细胞脱落、再生增殖和修复的动态平衡调节来发挥作用,这涉及每天更换多达 10 个细胞。这种 SI 中的动态转换为细胞毒性介导的 AOP/MOA 提供了一个独特的局部环境。进入十二指肠后,绒毛上皮细胞的细胞毒性是分子起始事件,表现为隐窝伸长、绒毛萎缩/变钝和其他形态变化。随着时间的推移,由于上皮细胞丢失加速,肠道上皮细胞的再生能力下降,尤其是在更高的暴露水平下。第一个关键事件(KE),持续的再生隐窝增殖/增生,由于广泛的修复能力,需要足够的时间,可能超过 6 或 12 个月,为第二个 KE,即自发性突变/转化创造更多机会,最终导致近端 SI 肿瘤。根据经合组织的指导意见,使用经过修改的布拉德福·希尔考虑因素评估了生物学合理性、必要性和经验支持。证据权重还包括在 Cr(VI)或克菌丹暴露长达 90 天后,十二指肠中未诱导突变。该 AOP 的大量证据,以及人类暴露的程度远低于该 AOP 中 KE 相关的暴露程度,支持其在监管应用中的使用,包括危害识别和风险评估。